JO3343B1 - أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها - Google Patents
أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامهاInfo
- Publication number
- JO3343B1 JO3343B1 JOP/2013/0216A JOP20130216A JO3343B1 JO 3343 B1 JO3343 B1 JO 3343B1 JO P20130216 A JOP20130216 A JO P20130216A JO 3343 B1 JO3343 B1 JO 3343B1
- Authority
- JO
- Jordan
- Prior art keywords
- carboxylic acids
- novel5
- aminotetrahydroquinoline
- ofdiseases
- prevention
- Prior art date
Links
- 230000002265 prevention Effects 0.000 abstract 2
- 230000002612 cardiopulmonary effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
يتعلق الاختراع الحالي مع 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids جديدة ، بعمليات (processes) لتحضيرها، باستخدامها لمعالجة و/أو منع أمراض، وباستخدامها لتحضير أدوية (medicaments) لمعالجة و/أو منع أمراض، بصفة خاصة لمعالجة و/أو منع اضطرابات القلب والأوعية الدموية.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12177284 | 2012-07-20 | ||
| EP13167967 | 2013-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3343B1 true JO3343B1 (ar) | 2019-03-13 |
Family
ID=48914233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2013/0216A JO3343B1 (ar) | 2012-07-20 | 2013-07-18 | أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها |
Country Status (40)
| Country | Link |
|---|---|
| US (3) | US8981104B2 (ar) |
| EP (1) | EP2875003B1 (ar) |
| JP (1) | JP6251259B2 (ar) |
| KR (1) | KR102137517B1 (ar) |
| CN (1) | CN104822661B (ar) |
| AR (1) | AR091838A1 (ar) |
| AU (1) | AU2013292046C1 (ar) |
| BR (1) | BR112015001211B1 (ar) |
| CA (1) | CA2879369C (ar) |
| CL (1) | CL2015000120A1 (ar) |
| CO (1) | CO7240369A2 (ar) |
| CR (1) | CR20150020A (ar) |
| CY (1) | CY1118588T1 (ar) |
| DK (1) | DK2875003T3 (ar) |
| DO (1) | DOP2015000012A (ar) |
| EA (1) | EA028918B9 (ar) |
| EC (1) | ECSP15001882A (ar) |
| ES (1) | ES2616036T3 (ar) |
| GT (1) | GT201500011A (ar) |
| HR (1) | HRP20170185T1 (ar) |
| HU (1) | HUE030540T2 (ar) |
| IL (1) | IL236616B (ar) |
| JO (1) | JO3343B1 (ar) |
| LT (1) | LT2875003T (ar) |
| ME (1) | ME02603B (ar) |
| MX (1) | MX360863B (ar) |
| MY (1) | MY172994A (ar) |
| NZ (1) | NZ702977A (ar) |
| PE (1) | PE20150350A1 (ar) |
| PH (1) | PH12015500106B1 (ar) |
| PL (1) | PL2875003T3 (ar) |
| PT (1) | PT2875003T (ar) |
| RS (1) | RS55651B1 (ar) |
| SG (2) | SG10201700454PA (ar) |
| SI (1) | SI2875003T1 (ar) |
| TN (1) | TN2015000026A1 (ar) |
| TW (1) | TWI598338B (ar) |
| UY (1) | UY34918A (ar) |
| WO (1) | WO2014012934A1 (ar) |
| ZA (1) | ZA201409394B (ar) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| JP6118965B2 (ja) | 2012-04-16 | 2017-04-26 | トーアエイヨー株式会社 | ２環性化合物 |
| WO2014012935A1 (de) | 2012-07-20 | 2014-01-23 | Bayer Pharma Aktiengesellschaft | Substituierte aminoindan- und aminotetralin-carbonsäuren und ihre verwendung |
| BR112015001211B1 (pt) * | 2012-07-20 | 2020-12-15 | Bayer Pharma Aktiengesellschaft | Ácidos 5-aminotetra-hidroquinolina-2-carboxílicos, processos para a sua preparação, seus usos no tratamento e/ou prevenção de doenças e seus medicamentos |
| FR3000065A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes |
| EP3204358B1 (en) | 2014-10-07 | 2018-09-19 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| US20180169095A1 (en) | 2015-05-06 | 2018-06-21 | Bayer Pharma Aktiengesellschaft | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) |
| CN113750102A (zh) | 2015-07-23 | 2021-12-07 | 拜耳制药股份公司 | 可溶性鸟苷酸环化酶的刺激剂和/或活化剂及其用途 |
| SG11201900360TA (en) * | 2016-07-22 | 2019-02-27 | Toa Eiyo Ltd | Therapeutic agent for glaucoma |
| CN109890379A (zh) | 2016-10-11 | 2019-06-14 | 拜耳制药股份公司 | 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品 |
| WO2018153899A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc) |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| JOP20200073A1 (ar) | 2017-10-24 | 2020-04-29 | Bayer Pharma AG | مركبات أميد إيميدازوبيريدين تحمل بدائل واستخداماتها |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| CN108218770A (zh) * | 2018-02-28 | 2018-06-29 | 南京波普生物医药研发有限公司 | 2-氯-7,8-二氢-6h-喹啉-5-酮的制备方法 |
| WO2019211081A1 (en) | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
| CA3100096A1 (en) | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
| US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
| CA3126778A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
| WO2020216669A1 (de) | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Phenylsubstituierte imidazopyridinamide und ihre verwendung |
| EP3966226B1 (en) | 2019-05-07 | 2025-12-24 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
| EP3822268A1 (en) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Substituted hydantoinamides as adamts7 antagonists |
| EP3822265A1 (en) | 2019-11-15 | 2021-05-19 | Bayer AG | Substituted hydantoinamides as adamts7 antagonists |
| MX2022014655A (es) | 2020-05-20 | 2022-12-15 | Bayer Ag | Proceso para preparar (5s)-5-({2-[4-(butoxicarbonil)fenil]etil}[2- (2-{[3-cloro-4'-(trifluorometil)[bifenil]-4-il]metoxi}fenil)etil] amino)-5,6,7,8-tetrahidroquinolin-2-carboxilato de butilo. |
| EP4456896A1 (en) | 2021-12-29 | 2024-11-06 | Bayer Aktiengesellschaft | Treatment of cardiopulmonary disorders |
| CA3244896A1 (en) | 2021-12-29 | 2023-07-06 | Bayer Aktiengesellschaft | Pharmaceutical dry powder inhalation formulation |
| CA3244893A1 (en) | 2021-12-29 | 2023-07-06 | Bayer Aktiengesellschaft | PROCESS FOR PREPARING (5S)-{[2-(4-CARBOXYPHENYL)ETHYL] |2-(2-{|3-CHLORO-4'-(TRIFLUOROMETHYL)BIPHENYL-4-YL]METHOXY}PHENYL)ETHYL]AMINOL-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC AND ITS CRYSTALLINE FORMS FOR USE AS A PHARMACEUTICALLY ACTIVE COMPOUND |
| EP4536205A1 (en) | 2022-06-09 | 2025-04-16 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8004002L (sv) | 1980-05-29 | 1981-11-30 | Arvidsson Folke Lars Erik | Terapeutiskt anvendbara tetralinderivat |
| IL65501A (en) | 1981-05-08 | 1986-04-29 | Astra Laekemedel Ab | 1-alkyl-2-aminotetralin derivatives,process for their preparation and pharmaceutical compositions containing them |
| DE3718317A1 (de) | 1986-12-10 | 1988-06-16 | Bayer Ag | Substituierte basische 2-aminotetraline |
| DE3719924A1 (de) | 1986-12-22 | 1988-06-30 | Bayer Ag | 8-substituierte 2-aminotetraline |
| DE69032725T2 (de) | 1989-05-31 | 1999-04-08 | Pharmacia & Upjohn Co., Kalamazoo, Mich. | ZNS-wirksame 8-Heterocyclyl-2-aminotetralin Derivate |
| FR2659853A1 (fr) | 1990-03-22 | 1991-09-27 | Midy Spa | Utilisation de derives 2-aminotetraliniques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale. |
| WO1995018617A1 (en) | 1994-01-10 | 1995-07-13 | Teva Pharmaceutical Industries Ltd. | 1-aminoindan derivatives and compositions thereof |
| CA2333951C (en) | 1998-06-01 | 2012-02-28 | Ortho-Mcneil Pharmaceutical, Inc. | Method for treating neurodegenerative disorders |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| GB9827467D0 (en) | 1998-12-15 | 1999-02-10 | Zeneca Ltd | Chemical compounds |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10109858A1 (de) | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige halogensubstituierte Aminodicarbonsäurederivate |
| DE10109861A1 (de) | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate |
| DE10109859A1 (de) | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige Aminodicarbonsäurederivate |
| DE10110750A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| US20050032873A1 (en) | 2003-07-30 | 2005-02-10 | Wyeth | 3-Amino chroman and 2-amino tetralin derivatives |
| GB0318094D0 (en) * | 2003-08-01 | 2003-09-03 | Pfizer Ltd | Novel combination |
| WO2006104826A2 (en) | 2005-03-30 | 2006-10-05 | Merck & Co., Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| DE102005047946A1 (de) * | 2005-10-06 | 2007-05-03 | Bayer Healthcare Ag | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten |
| DE102005050377A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclische Verbindungen und ihre Verwendung |
| DE102006031175A1 (de) * | 2006-07-06 | 2008-01-10 | Bayer Healthcare Ag | Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur |
| WO2009023669A1 (en) | 2007-08-13 | 2009-02-19 | Janssen Pharmaceutica N.V. | Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof |
| CN101939053A (zh) | 2007-09-06 | 2011-01-05 | 默沙东公司 | 可溶性的鸟苷酸环化酶活化剂 |
| JP5937353B2 (ja) * | 2008-08-19 | 2016-06-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ | 冷感−メントール受容体拮抗剤 |
| DE102010020553A1 (de) | 2010-05-14 | 2011-11-17 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| US20130158028A1 (en) | 2010-06-25 | 2013-06-20 | Bayer Intellectual Property Gmbh | Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes |
| PH12013500055A1 (en) | 2010-07-09 | 2017-08-23 | Bayer Ip Gmbh | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| JP5715713B2 (ja) | 2011-03-10 | 2015-05-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性グアニル酸シクラーゼ活性化因子 |
| JP6118965B2 (ja) * | 2012-04-16 | 2017-04-26 | トーアエイヨー株式会社 | ２環性化合物 |
| BR112015001211B1 (pt) * | 2012-07-20 | 2020-12-15 | Bayer Pharma Aktiengesellschaft | Ácidos 5-aminotetra-hidroquinolina-2-carboxílicos, processos para a sua preparação, seus usos no tratamento e/ou prevenção de doenças e seus medicamentos |
| WO2014012935A1 (de) | 2012-07-20 | 2014-01-23 | Bayer Pharma Aktiengesellschaft | Substituierte aminoindan- und aminotetralin-carbonsäuren und ihre verwendung |
-
2013
- 2013-07-16 BR BR112015001211-6A patent/BR112015001211B1/pt active IP Right Grant
- 2013-07-16 DK DK13744464.2T patent/DK2875003T3/en active
- 2013-07-16 SG SG10201700454PA patent/SG10201700454PA/en unknown
- 2013-07-16 EA EA201590251A patent/EA028918B9/ru not_active IP Right Cessation
- 2013-07-16 WO PCT/EP2013/065017 patent/WO2014012934A1/de not_active Ceased
- 2013-07-16 PE PE2015000049A patent/PE20150350A1/es active IP Right Grant
- 2013-07-16 HR HRP20170185TT patent/HRP20170185T1/hr unknown
- 2013-07-16 KR KR1020157001058A patent/KR102137517B1/ko active Active
- 2013-07-16 JP JP2015522074A patent/JP6251259B2/ja active Active
- 2013-07-16 PL PL13744464T patent/PL2875003T3/pl unknown
- 2013-07-16 NZ NZ702977A patent/NZ702977A/en unknown
- 2013-07-16 HU HUE13744464A patent/HUE030540T2/en unknown
- 2013-07-16 MX MX2015000739A patent/MX360863B/es active IP Right Grant
- 2013-07-16 CA CA2879369A patent/CA2879369C/en active Active
- 2013-07-16 ME MEP-2017-30A patent/ME02603B/me unknown
- 2013-07-16 ES ES13744464.2T patent/ES2616036T3/es active Active
- 2013-07-16 MY MYPI2015000125A patent/MY172994A/en unknown
- 2013-07-16 SI SI201330514A patent/SI2875003T1/sl unknown
- 2013-07-16 RS RS20170110A patent/RS55651B1/sr unknown
- 2013-07-16 CN CN201380048579.2A patent/CN104822661B/zh active Active
- 2013-07-16 PT PT137444642T patent/PT2875003T/pt unknown
- 2013-07-16 SG SG11201408421TA patent/SG11201408421TA/en unknown
- 2013-07-16 AU AU2013292046A patent/AU2013292046C1/en active Active
- 2013-07-16 EP EP13744464.2A patent/EP2875003B1/de active Active
- 2013-07-16 LT LTEP13744464.2T patent/LT2875003T/lt unknown
- 2013-07-18 AR ARP130102566A patent/AR091838A1/es active IP Right Grant
- 2013-07-18 JO JOP/2013/0216A patent/JO3343B1/ar active
- 2013-07-18 US US13/945,675 patent/US8981104B2/en active Active
- 2013-07-19 TW TW102125865A patent/TWI598338B/zh active
- 2013-07-19 UY UY0001034918A patent/UY34918A/es active IP Right Grant
-
2014
- 2014-12-19 ZA ZA2014/09394A patent/ZA201409394B/en unknown
-
2015
- 2015-01-11 IL IL236616A patent/IL236616B/en active IP Right Grant
- 2015-01-14 PH PH12015500106A patent/PH12015500106B1/en unknown
- 2015-01-15 CO CO15007422A patent/CO7240369A2/es unknown
- 2015-01-16 DO DO2015000012A patent/DOP2015000012A/es unknown
- 2015-01-16 CL CL2015000120A patent/CL2015000120A1/es unknown
- 2015-01-19 EC ECIEPI20151882A patent/ECSP15001882A/es unknown
- 2015-01-19 TN TNP2015000026A patent/TN2015000026A1/fr unknown
- 2015-01-20 GT GT201500011A patent/GT201500011A/es unknown
- 2015-01-20 CR CR20150020A patent/CR20150020A/es unknown
- 2015-01-29 US US14/609,122 patent/US9688636B2/en active Active
-
2017
- 2017-02-03 CY CY20171100161T patent/CY1118588T1/el unknown
- 2017-05-19 US US15/600,132 patent/US10053428B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3343B1 (ar) | أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها | |
| WO2015073587A3 (en) | Synthetic membrane-receiver complexes | |
| AU355322S (en) | Chair | |
| AU346731S (en) | 1. Chair without arms 2. chair with arms | |
| AU352197S (en) | Hitch step | |
| MX2017008423A (es) | Formulaciones transdérmicas. | |
| IN2015DN01524A (ar) | ||
| MX362070B (es) | Polioles que contienen tanino, su producción y su uso. | |
| IN2014DN11078A (ar) | ||
| GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same | |
| IN2014DN06738A (ar) | ||
| AU352917S (en) | Trailer jack | |
| IN2014DN07191A (ar) | ||
| Wickelgren | The education of character | |
| PH12016502311A1 (en) | Omega-3 analogues | |
| AU356192S (en) | Shelving unit | |
| PH12016501658A1 (en) | Sialylated glycoprotein compositions and uses thereof | |
| MX2015000804A (es) | Composiciones y metodos para tratar el sarcoma de ewing y otros trastornos relacionados con ews-fli1. | |
| MX345908B (es) | Sistema de energía comestible. | |
| MY184721A (en) | Use of odiparcil in the treatment of a mucopolysaccharidosis | |
| MX2015009161A (es) | Polioles, su preparación y su uso. | |
| AU346989S (en) | Coupling nut | |
| UA80618U (en) | Use of n-steroylethanolamine as radiomodifier | |
| UA75621U (uk) | Застосування капсул "фітовенол" як лікувально-профілактичного засобу з антитромботичною дією | |
| CA146003S (en) | Anti-wrinkle device |